NCT00751114 - Evaluation of Insulin Glargine Versus Sitagliptin in Insulin-naive Patients | Biotech Hunter

Enrollment

515

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

Insulin Glargine

Subcutaneous injection. 100 Units/mL solution for injection in a pre-filled SoloStar® pen (3 mL).

DRUG

Sitagliptin

Oral administration. 100 mg film-coated tablets.

DRUG

Metformin

Patients continued with metformin as usual oral anti-diabetic treatment.

Trial Locations (17)

Sanofi-Aventis Administrative Office, Bridgewater

Sanofi-Aventis Administrative Office, Vienna

Sanofi-Aventis Administrative Office, São Paulo

Sanofi-Aventis Administrative Office, Bogotá

Sanofi-Aventis Administrative Office, Cairo

Sanofi-Aventis Administrative Office, Kallithea

Sanofi-Aventis Administrative Office, Hong Kong

Sanofi-Aventis Administrative Office, Mumbai

Sanofi-Aventis Administrative Office, Netanya

Sanofi-Aventis Administrative Office, Beirut

Sanofi-Aventis Administrative Office, Col. Coyoacan

Sanofi-Aventis Administrative Office, Gouda

Sanofi-Aventis Administrative Office, Porto Salvo

Sanofi-Aventis Administrative Office, Seoul

Sanofi-Aventis Administrative Office, Barcelona

Sanofi-Aventis Administrative Office, Istanbul

Sanofi-Aventis Administrative Office, Guildford Surrey